Krause Kevin Michael 4
4 · AN2 Therapeutics, Inc. · Filed Jan 11, 2024
Insider Transaction Report
Form 4
Krause Kevin Michael
Chief Strategy Officer
Transactions
- Exercise/Conversion
Common Stock
2024-01-09$6.60/sh+5,000$33,000→ 9,331 total - Sale
Common Stock
2024-01-09$20.14/sh−7,417$149,367→ 1,914 total - Exercise/Conversion
Common Stock
2024-01-09$0.42/sh+2,417$1,015→ 4,331 total - Exercise/Conversion
Stock Option (right to buy)
2024-01-09−2,417→ 49,868 totalExercise: $0.42Exp: 2030-01-22→ Common Stock (2,417 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-01-09−5,000→ 26,832 totalExercise: $6.60Exp: 2031-04-29→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
- [F4]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.